Introducing Sobi's Commitment to the Haemophilia Community
Swedish Orphan Biovitrum AB (publ) (Sobi) is thrilled to announce its participation in the 19th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD). This event, held in February 2026, promises to be a significant platform for sharing knowledge and advancing treatments for haemophilia and related disorders. Sobi's involvement underscores its commitment to improving the lives of patients suffering from rare blood disorders, illustrating the company’s dedication to innovative therapies.
Exciting Presentations of Haemophilia Data
During EAHAD 2026, Sobi plans to present compelling new data gathered from recent studies, including seven scientific abstracts showcasing the latest findings in haemophilia treatment. One of the highlights will be an oral presentation detailing three years of clinical results from the XTEND-ed study involving Altuvoct, a novel treatment option that reflects Sobi's ongoing dedication to advancing haemophilia care.
Key Insights into Altuvoct Treatment
According to Lydia Abad-Franch, MD, Head of R&D and Medical Affairs at Sobi, the findings from the XTEND-ed study reflect the long-term efficacy and safety of Altuvoct prophylaxis in patients with haemophilia A. With treatment continuing to demonstrate excellent protection against bleeding episodes, the data supports Sobi's commitment to scientific excellence. The well-managed few bleeding events and the absence of unexpected safety concerns reaffirm the potential of Altuvoct as a vital therapy in the field.
"Haemophilia is a severe chronic disease, and our mission is to advance the science for those living with this condition. We believe that Altuvoct represents a significant step forward in treatment options for these patients," Dr. Abad-Franch emphasized.
Overview of Sobi's Research Contributions at EAHAD
Sobi will present several important findings at EAHAD 2026. Key topics covered include:
- Efanesoctocog Alfa Prophylaxis: Presenting third interim results on the long-term extension study of Efanesoctocog Alfa.
- Physical Activity and Efficacy: Exploring how Efanesoctocog Alfa impacts the quality of life for patients with severe haemophilia A.
- Long-Term Outcomes: A detailed analysis on treatment outcomes from the XTEND-ed study.
- Management of Bleeding Episodes: Insight into treatment effectiveness in various age groups, including adults, adolescents, and children.
- Real-World Insights: Findings from the CHESS III Study addressing patient-physician alignment and quality of life reports associated with joint health.
About Altuvoct® (efanesoctocog alfa)
ALTUVOCT® (efanesoctocog alfa) plays a crucial role in treating patients with haemophilia A. Its indication for both treatment and prophylaxis makes it a versatile option for diverse age groups and varying disease severities, highlighting Sobi's commitment to addressing critical healthcare needs.
Collaborative Efforts: Sobi and Sanofi
In partnership with Sanofi, Sobi is at the forefront of developing and commercializing ALTUVOCT (efanesoctocog alfa), branded as ALTUVIIIO™ in the United States. This collaboration allows for shared expertise across regions, benefiting patients worldwide as Sobi handles the development and commercialization in Europe, North Africa, and the Middle East, while Sanofi oversees North America and other territories.
Who is Sanofi?
Sanofi is a biopharmaceutical powerhouse dedicated to arriving at innovative solutions that enhance the quality of life through advanced medicines and vaccines. They integrate artificial intelligence and a deep understanding of the immune system to tackle various health challenges while continuously expanding their groundbreaking product pipeline.
The Sobi Mission
Sobi is a global leader in the biopharma field, committed to unlocking breakthroughs that transform the lives of individuals encountering rare diseases. With approximately 1,900 employees spread across multiple continents and an impressive revenue record, Sobi’s share is listed on Nasdaq Stockholm (STO:SOBI). Their focus on innovation continues to propel them toward positive impacts within the communities they serve.
Frequently Asked Questions
What is Altuvoct used for?
Altuvoct is indicated for the treatment and prevention of bleeding in patients with haemophilia A, supporting various age groups and severity levels.
What is the main focus of Sobi at EAHAD 2026?
Sobi will present critical research results related to haemophilia, highlighting treatment efficacy, safety, and patient outcomes.
What partnerships does Sobi have in its research efforts?
Sobi collaborates with Sanofi for the development and commercialization of Altuvoct (efanesoctocog alfa), enhancing patient access across different regions.
How many employees does Sobi have?
Sobi employs approximately 1,900 personnel worldwide, emphasizing its commitment to innovation in healthcare.
What is Sobi's impact on the haemophilia community?
Sobi is dedicated to advancing treatments and improving the quality of life for patients affected by rare blood disorders through innovative research and development.
